Second Merck deal takes Lycera's autoimmune quiver to potential $600m+
This article was originally published in Scrip
Executive Summary
Lycera's second collaboration with Merck, which is worth more than $300 million in upfront and future milestone fees plus royalties, gives the Ann Arbor, Michigan-based company a third drug discovery and development program focused on selective small molecule immune-modulators to treat autoimmune diseases.